Cleared Traditional

K163260 - SeptiCyte LAB (FDA 510(k) Clearance)

Feb 2017
Decision
88d
Days
Class 2
Risk

K163260 is an FDA 510(k) clearance for the SeptiCyte LAB. This device is classified as a Rt-qpcr Assay For Mrna Transcript Immune Biomarkers (Class II - Special Controls, product code PRE).

Submitted by Immunexpress, Inc. (Seattle, US). The FDA issued a Cleared decision on February 17, 2017, 88 days after receiving the submission on November 21, 2016.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3215. A Quantitative Gene Expression Assay Using Reverse Transcription Polymerase Chain Reaction To Quantify The Relative Expression Levels Of Host Response Genes Isolated From Whole Blood..

Submission Details

510(k) Number K163260 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 21, 2016
Decision Date February 17, 2017
Days to Decision 88 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code PRE - Rt-qpcr Assay For Mrna Transcript Immune Biomarkers
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3215
Definition A Quantitative Gene Expression Assay Using Reverse Transcription Polymerase Chain Reaction To Quantify The Relative Expression Levels Of Host Response Genes Isolated From Whole Blood.